AMPATH Lab: Lung Cancer Ngs Panel

What Is the Lung Cancer Basic Panel (NGS) and How Does It Help in Early Detection?

Lung cancer continues to be a major global health concern, but advancements in diagnostic technology are improving outcomes. One such breakthrough is the Lung Cancer Basic Panel, powered by Next-Generation Sequencing (NGS). This advanced test helps identify genetic mutations in lung cancer cells, enabling more precise diagnosis and targeted treatment.

What is a Lung Cancer Basic Panel (NGS)?

The Lung Cancer Basic Panel is a molecular diagnostic test that analyzes the genetic makeup of lung cancer cells using NGS technology. Unlike traditional testing methods that check for one mutation at a time, NGS allows simultaneous analysis of multiple cancer-related genes.

This broad genetic screening identifies key biomarkers—specific mutations or alterations that influence how the cancer behaves and responds to therapy. The panel typically examines mutations in important genes, including:

EGFR (Epidermal Growth Factor Receptor)
ALK (Anaplastic Lymphoma Kinase)
ROS1 (ROS Proto-Oncogene 1)
BRAF (B-Raf Proto-Oncogene)
KRAS (Kirsten Rat Sarcoma Viral Oncogene Homolog)
MET (MET Proto-Oncogene, Receptor Tyrosine Kinase)
RET (Ret Proto-Oncogene)

By identifying these biomarkers, the panel helps oncologists understand the tumor’s genetic structure and choose the most effective treatment options.

How NGS Technology Powers Early Detection

Next-Generation Sequencing is a high-throughput technology that reads millions of DNA fragments at once. Here’s how the process works in lung cancer testing:

Sample Collection: A biopsy sample is collected from the tumor, or in some cases, a liquid biopsy is performed to detect circulating tumor DNA (ctDNA).
DNA/RNA Extraction: Genetic material is isolated from the sample.
Library Preparation: DNA/RNA fragments are processed and tagged with adapters for sequencing.
Sequencing: Millions of fragments are sequenced simultaneously using NGS technology.
Data Analysis: Software compares tumor DNA to reference sequences to identify mutations.
Reporting: A detailed report highlights clinically relevant genetic alterations.

This detailed genetic insight helps guide decision-making even in early-stage lung cancer.

Role of the Panel in Early-Stage Lung Cancer

While commonly used in advanced lung cancer cases, the panel’s value in early detection is increasing. Early genetic insights allow doctors to:

Confirm diagnosis more accurately
Identify high-risk mutations early
Tailor treatment before the cancer progresses

Benefits of the Lung Cancer Basic Panel

Enables Targeted Therapy: Identifies actionable mutations, allowing the use of targeted drugs such as EGFR or ALK inhibitors, which are often more effective and have fewer side effects.
Provides a Comprehensive Profile: A single test reveals multiple genetic alterations, saving time and preserving tissue.
Offers Prognostic Insights: Some mutations indicate how aggressive the tumor is, helping doctors plan treatment accordingly.
Identifies Clinical Trial Options: The genetic data may match patients with ongoing trials for new therapies.

These advantages support a personalized approach to cancer treatment, improving outcomes and reducing unnecessary treatments.

Conclusion

At AMPATH Labs, we are committed to providing advanced diagnostic solutions that support precise and effective patient care. Our Lung Cancer Basic Panel (NGS) offers a powerful tool for identifying genetic mutations that drive lung cancer, enabling early detection and optimized treatment planning. With cutting-edge technology and expert analysis, we help clinicians make informed decisions for better patient outcomes.